HCV Infection Could Be Rare in the U.S. by 2036

This scenario assumes use of onetime birth-cohort screening and next-generation treatment regimens, which would need to be widely available.

Implementation of newly recommended, onetime birth-cohort screening for hepatitis C virus (HCV) infection and the development of direct-acting antivirals (DAAs) are expected to reduce HCV-related disease burden in the U.S. To quantify that potential decreased burden, researchers employed an individual-level, state-transition simulation model of the HCV-infected U.S. population from 2001 to 2050, taking into account the new DAA regimens, treatment capacity, and screening policy.

The population was characterized using nationwide U.S. survey data. The simulation assumed treatment with peginterferon plus ribavirin with or without protease inhibitor (triple therapy) between 2013 and 2014, the first-wave, next-generation all-oral regimens after 20…

Reviewing Author

Atif Zaman, MD, MPH

Disclosures

Nothing to disclose

Atif Zaman, MD, MPH

Disclosures

Nothing to disclose

HCV Infection Could Be Rare in the U.S. by 2036

Topics

Reviewing Author